Primitive neuroectodermal tumors (PNETs) are a family of primary malignant brain tumors that include medulloblastomas. Although genetic models of a subset of medulloblastomas are documented over the past decade, the molecular basis of other subclasses of PNET remains unclear. As elevated c-Myc expression, activation of Wnt/b-catenin signaling and dysfunction of p53 are seen in human PNETs, we investigated what role these abnormalities have in the formation of PNETs. Incorporating these abnormalities, we generated supratentorial PNET (sPNET) in mice using somatic cell gene transfer. We show that sPNETs arise from GFAP-expressing cells by forced c-Myc expression combined with p53 inactivation. b-catenin activation promotes tumor progression and induces divergent differentiation. These c-Myc þ b-catenin-induced PNETs are histologically similar to large cell/anaplastic medulloblastomas and can occur in both cerebrum and cerebellum. Furthermore, we have obtained one PNET with marked epithelial differentiation having histological resemblance to choroid plexus carcinoma in this series. Our results in mice suggest that sPNET with varied differentiation and large cell/anaplastic medulloblastomas may be two tumor groups with similar genetic foundations. These data provide insights into the biology and classification of human PNETs and suggest that multiple tumor types or variants can be generated from a fixed set of genetic abnormalities.
Introduction
Primitive neuroectodermal tumors (PNETs) are characterized by poorly differentiated neuroepithelial cells that have the capacity for divergent differentiation. Although the concept of PNETs defining a family of tumors with heterogeneous differentiation characters has been controversial for more than a decade, the term PNETs is now generally used for a subgroup of medulloblastoma, medulloepithelioma, ependymoblastoma, atypical teratoid-rhabdoid tumor and supratentorial PNET (sPNET) that develops in cerebrum. Choroid plexus tumors are not currently classified as PNETs (Louis et al., 2007) , however, there is a case report of a sPNET with choroid plexus differentiation (Janzer and Kleihues, 1985) .
Most genetic analysis of the PNET family has been done on medulloblastomas. Mouse models of medulloblastomas indicate the major involvement of hedgehog signaling (Goodrich et al., 1997; Weiner et al., 2002) and p53 (Marino et al., 2000; Wetmore et al., 2001) . Although c-Myc activation has been reported to enhance medulloblastoma formation in combination with sonic hedgehog (Rao et al., 2003) , c-Myc alone has not been sufficient to induce brain tumors in mice (Fults et al., 2002; Rao et al., 2003) . sPNETs are rare tumors and genetic alterations in them have not been fully characterized. However, reports have suggested the presence of genetic abnormalities in sPNETs, including somatic and germline mutation of p53 Reifenberger et al., 1998; Kraus et al., 2002) , b-catenin mutation (Koch et al., 2001) , losses of chromosome 14q and 19q (Russo et al., 1999) and expression of the NeuroD family (Rostomily et al., 1997) .
Even though the p53 mutation has been identified in less than 10% of both human medulloblastomas (Saylors et al., 1991; Adesina et al., 1994) and sPNETs Kraus et al., 2002) , p53 immunopositivity implying p53 dysfunction can be found in tumors with wild-type p53. A recent study has demonstrated that immunoreactivity to p53 was detected in 18% of classic and desmoplastic medulloblastomas, 45% of large cell/anaplastic medulloblastomas and 88% of sPNET (Eberhart et al., 2005) . These data suggest that p53 function is disrupted by mechanisms other than mutation of the p53 gene in the majority of sPNETs.
Here, we show that large cell/anaplastic variant of PNETs can arise in p53 À/À mice by c-Myc somatic cell gene transfer. We also demonstrate the combination effect of b-catenin on tumor progression and differentiation. Using mouse modeling of human cancer, we identify putative genetic causes and provide insights into the classification of rare human tumors.
Results

RCAS/tv-a system in tumor formation
To investigate the molecular basis of sPNET, we modeled the formation of these tumors in mice. We used transgenic mouse line (Gtv-a) that expresses TV-A under the control of the GFAP gene promoter and retroviral vector (replication competent ALV splice acceptor (RCAS)), which allows postnatal somatic gene transfer of c-Myc and b-catenin. To mimic loss of p53 function we used a p53 À/À background. We transferred full-length human wild-type c-Myc and human mutant b-catenin (b-cateninS37A, which renders stabilized b-catenin protein) to glial fibrillary acidic protein (GFAP)-expressing cells present in the brain of neonatal mice born within 48 h using RCAS vectors (Supplementary Figure 1a ). All these DNA constructs and mouse genotypes were confirmed by DNA sequencing and PCR genotyping . Because a substantial percentage of p53 À/À mice develop lymphoma and sarcoma after 3 months and more than 90% of them die within 6 months (Jacks et al., 1994) , we terminated our experiment at 3 months of age. To verify that tumor cells were derived from RCAS infection, we performed fluorescent in situ hybridization using an RCAS-specific DNA probe. We chose a region of spontaneous metastatic lymphoma adjacent to the RCAS-c-Myc-induced tumor as a negative control, and identified multiple RCAS integrations only in the RCAS-driven tumor (Supplementary Figure 1b) .
c-Myc-induced sPNETs First, we tested RCAS-mediated c-Myc somatic cell gene transfer in Gtv-a p53 À/À mice and obtained 15 tumors out of 43 Gtv-a p53 À/À mice (Figure 1 ). These c-Myc-induced tumors were located in the ventricle in 53% cases. Forty-seven percent of these tumors were located in parenchyma, whereas four tumors were infiltrating the brain structure. Tumors showed necrosis in 67% cases, hemorrhage in 47% cases and calcification in 7% cases, which are frequently seen in human sPNET. These tumors had histopathological features of PNET including carrot-shaped hyperchromatic nuclei, nuclear wrapping and apoptotic and mitotic cells. These histological findings were also similar to large cell/ anaplastic medulloblastomas, which account for up to 24% of medulloblastomas (Eberhart et al., 2002) , and are reported to frequently have a disrupted p53 pathway and c-Myc gene amplification (Brown et al., 2000; Frank et al., 2004) . Electron microscopy showed junctional complex that indicate epithelial differentiation, implying multivaried differentiating activity. Immunostaining revealed a high Ki-67 labeling index (70-100%) of these tumors and strong expression of nuclear c-Myc, suggesting an oncogenic role for c-Myc.
c-Myc þ b-catenin-induced sPNETs b-catenin signaling elevates c-Myc , cooperates with p53 deficiency (Pauklin et al., 2005) and b-catenin mutation has been found in sPNET (Koch et al., 2001) . We, therefore, investigated the effect of somatic cell gene transfer of mutant b-catenin (S37A) in combination with c-Myc in this system. We first addressed the possibility that b-catenin signaling may contribute to PNET tumorigenesis. Expression of stabilized b-catenin in the brains of p53 þ / þ mice does not result in brain tumor development (Fults et al., 2002; Kratz et al., 2002) . We tested RCAS mediated b-catenin somatic cell gene transfer in 12 Gtv-a p53 þ / þ mice and 8 Gtv-a p53 À/À mice, but did not obtain brain tumors. We then tested b-catenin somatic cell gene transfer in combination with c-Myc. We obtained 10 tumors out of 31 Gtv-a p53 À/À mice ( Figure 2 ). These tumors were located in the ventricle in 90% cases, and some early lesions originated from subependymal zone. Tumors showed necrosis in 70% of the cases, hemorrhage in 90% of the cases and calcification in 50% of the cases. The c-Myc þ b-catenin-induced tumors tended to be less invasive showing parenchymal (10%) and no diffuse (0%) tumors compared with c-Mycalone-induced tumors (47 and 27%, respectively, not significantly different). Large hemorrhages tended to be more common in c-Myc þ b-catenin-induced tumors than in c-Myc-alone-induced tumors (40 vs 7%, not statistically significant). Calcifications were seen more commonly in c-Myc þ b-catenin-induced tumors with a significant difference between the groups (50 vs 7%, P ¼ 0.023). The tendency was for b-catenin to widen the spectrum of differentiation of our sPNETs. Many of the individual observation did not reach statistical significances partly due to the numerous tumor variants modeled in this system and the large number of mice that would be required under these circumstances to reach significance. (Anwer et al., 1989) , bone has not been described to our knowledge. Osseous components in this tumor may represent a unique pattern of divergent differentiation in this PNET model. Interestingly, nuclear b-catenin was almost absent in the bone-forming regions. Primitive neuroepithelial rosettes resembling ependymal or ependymoblastic type were seen in three c-Myc þ b-catenin-induced tumors. Of note, rosette regions in these tumors lacked nuclear b-catenin as well. By contrast, cytokeratin 18 was highly expressed in the rosette cells, suggesting that the downregulation of b-catenin promoted epithelial differentiation. We also found that GFAP expressing tumor cells lacked nuclear b-catenin in c-Myc þ b-catenininduced tumors (data not shown). These results were consistent with published reports showing that the b-catenin signaling constitutes a switch regulating proliferation vs differentiation, and that disruption of b-catenin signaling induces differentiation in epithelium and mesenchyme (van de Wetering et al., 2002; Hill et al., 2005) . Our findings suggested that b-catenin activity inversely correlates with epithelial, mesenchymal and glial differentiation in sPNETs.
Divergent differentiation in sPNETs
To determine whether these mouse tumors had the divergent differentiation seen in human sPNETs, we performed further histochemical analysis. These tumors contained various focal cell clusters expressing the neuronal markers NeuN or TUJ1, glial marker GFAP, smooth muscle marker smooth muscle actin or epithelial marker cytokeratin 18. The expression of differentiated neuronal marker, NeuN, was more commonly seen in c-Myc-alone-induced tumors than in c-Myc þ b-catenininduced tumors (67 vs 10%, P ¼ 0.007), whereas undifferentiated neuronal marker, TUJ1, was commonly seen in both groups (73 vs 100%, P ¼ 0.108). GFAP expression was seen in both c-Myc-aloneinduced and c-Myc þ b-catenin-induced tumors (67 vs 100%, P ¼ 0.057). Smooth muscle actin expression also existed in both groups (67 vs 100%, P ¼ 0.057). Cytokeratin 18 expression was seen in only one case of c-Myc-alone-induced tumor (with marked epithelial differentiation), while staining for this marker was commonly seen in c-Myc þ b-catenin-induced tumors (6.7 vs 90%, Po0.001). c-Myc þ b-catenin-induced tumors tended to have focal differentiated cell clusters more than c-Myc-alone-induced tumors, implying that b-catenin affects differentiation of the resultant tumor (representative data are shown in Figure 3 ). The staining results are summarized in Table 1 . These data suggested that these mouse sPNETs had the capacity for neuronal, glial, mesenchymal and epithelial differentiation and, therefore, appear to be histologically similar to human sPNETs. Of note, these various histologies were all generated by the same set of genetic abnormalities, that is, p53 loss with c-Myc and b-catenin overexpression.
sPNETs in p53
þ / þ mice, and tumor incidence and latency of all sPNETs Loss of p53 appeared to be important for formation of these tumors as we obtained only one small c-Mycalone-induced tumor out of 31 Gtv-a p53 þ / þ mice and Figure 2d) . Histology of this tumor was almost the same as other sPNET in p53 À/À mice, and there was occasional p53 staining within the tumor (Figure 4a ). We performed DNA sequencing analysis for p53 exon 1-11 of this tumor, but no mutation was found (data not shown). These data support the idea that there are some mechanisms of p53 inactivation for the PNET development other than germline or somatic mutation. The summary of tumor incidence and latency is shown in Figures 4b and c . Tumor incidences were studied histologically, with the mice killed at 12 weeks of age or earlier. Tumor latencies were the mean times of symptom onset in mice with histologically verified tumors, therefore calculated by observing natural course of tumors after 12 weeks in some cases. Somatic cell gene transfer of c-Myc resulted in 34% incidence in p53 À/À mice but 3% in p53 þ / þ mice. When b-catenin was combined with c-Myc injection, tumor incidence was not changed although latency was shortened significantly from 14 to 8 weeks (Po0.001). These results suggested that b-catenin does not contribute to tumor initiation but does promote progression.
Large cell/anaplastic medulloblastomas in Gtv-a p53 À/À mice As large cell/anaplastic medulloblastomas arose in cerebellum, we tested cerebellar injection of c-Myc þ bcatenin in Gtv-a p53 À/À and Gtv-a p53 þ / þ mice. We obtained tumors in the cerebellum with the same histology as the above sPNETs at high incidence (five tumors out of six p53 À/À mice, a representative tumor is shown in Figure 5 ), whereas no tumor developed in five p53 þ / þ mice. The tumor incidence of large cell/ anaplastic medulloblastomas was greater than sPNET induced by c-Myc þ b-catenin in Gtv-a p53 À/À mice (83 vs 32%, P ¼ 0.031), and latency was shorter (6 vs 8 weeks, P ¼ 0.007). Bone formation with nearly absent bcatenin expression was also seen in these tumors as well as sPNETs. These results suggest that this PNET model includes not only sPNET but also large cell/anaplastic variant of medulloblastomas. Our data is also consistent with a recent report showing that large cell/anaplastic medulloblastomas arise from GFAP expressing cells in cooperation with p53 and Rb inactivations in mice (Shakhova et al., 2006) . The report indicates the role of N-Myc and Ptch2 on tumorigenesis, rather than the cMy and b-catenin demonstrated here, suggesting similar downstream targets and effects.
sPNET with epithelial differentiation One of 43 Gtv-a p53 À/À mice infected with RCAS-c-Myc generated a sPNET with marked epithelial differentiation ( Figure 6 ). The tumor histologically resembled choroid plexus carcinoma, a malignant subtype of choroid plexus tumors. Because of the unique histology and singular incidence, we verified that this tumor was induced by RCAS gene transfer by confirming the integration of RCAS construct in the tumor DNA using florescence in situ hybridization. Of interest, only one RCAS integration was detected by fluorescent in situ (Su et al., 2006) . c-Myc is a known downstream target of Wnt signaling and also important in medulloblastoma pathogenesis. c-Myc is commonly amplified in the biologically aggressive large cell/anaplastic medulloblastoma subtype (Leonard et al., 2001) . However, the ability of c-Myc gene transfer to nestin-expressing cells in the developing cerebellum to induce medulloblastoma is limited (Rao et al., 2003) . As oncogene-induced proliferation is not sufficient for tumor initiation unless apoptosis is blocked (Green and Evan, 2002) , we combined p53 loss to initiate tumor formation. The same approach has been reported in a recent study using the RCAS system, which shows that blocking apoptosis by overexpressing Bcl-2 enhances medulloblastoma formation in mice (McCall et al., 2007) . In the present study, we show that loss of p53 is required for c-Myc to initiate tumor formation, suggesting the antiapoptotic effects of p53 loss contribute greatly to the c-Myc induced oncogeneisis. Our results suggest that the tumor promoting effect of b-catenin may be mediated by nonmyc targets of b-catenin rather than its ability to increase c-Myc levels; the expression level of c-Myc in c-Myc þ b-catenin-induced tumors was almost same as in c-Myc-alone-induced tumors. These unknown targets of b-catenin on differentiation may contribute to the morphological effects on the tumors as well. As a model of the human PNET family, the mouse tumors show a somewhat different distribution of different characteristics than that seen in humans. For example, whereas large cells with prominent nucleoli resembling human large cell medulloblastoma predominate in our mice, large cell histology is seen in the minority of human PNET. And although one of our cases showed marked epithelial differentiation, this phenomenon is uncommon in human examples of PNET (Janzer and Kleihues, 1985) . Nonetheless, these phenomena might be explained by the fact that these genetic combination models are only a subset of the PNET family.
It is still controversial whether the same PNET can arise in the cerebrum (supratentorial) and cerebellum (infratentorial) in humans. We observed early lesions located in subependymal zone of the lateral and fourth ventricles, suggesting that these tumors may be derived from subependymal matrix cells known to express GFAP in both cerebrum and cerebellum. Unfortunately, it is not possible to know what cell is being targeted other than if it is GFAP expressing. It is possible that more mature astrocytes are driven to 'dedifferentiate' under these conditions. It is also possible that GFAP-expressing multipotent stem cells are serving as the cell of origin for these tumors, especially considering the divergent differentiation observed. Our mouse models indicate that the histologically similar tumors caused by the same genetic alterations may occur in the distinct sites with different tumor incidence and latency.
The sPNET with epithelial differentiation resembling choroid plexus carcinoma in our series is intriguing. There is increasing evidence in the literature indicating molecular and genetic similarity of choroid plexus tumors to PNETs. For example, choroid plexus tumors can occur in the parenchyma as PNETs do (Pillai et al., 2004) . Choroid plexus tumors (CPTs) have developed in patients with the Li-Fraumeni (Yuasa et al., 1993; Vital et al., 1998) , although no p53 mutation has been reported in spontaneous CPTs (Ohgaki et al., 1993) . Nonetheless, spontaneous choroid plexus tumors show p53 immunopositivity implying dysregulation of p53 function as seen in PNETs (Jay et al., 1996; Carlotti et al., 2002) . Inactivation of hSNF5/INI-1 is seen in both choroid plexus carcinomas and atypical teratoidrhabdoid tumors that is classified as a subgroup of PNETs (Sevenet et al., 1999; Gessi et al., 2003) . Several families of rare tumors exist, such as PNETs, brain stem gliomas or spinal cord tumors. Each of these families are comprised of tumors with divergent histology and it is not clear whether they represent variants of one basic genetic neoplasm or are different tumor types with different genetics found in the same organ site. In this report we use mouse modeling to demonstrate that a single set of genetic abnormalities can give rise to divergent histology found in one of these families similar to that found in the human counterpart.
Materials and methods
Generation of p53
À/À Gtv-a double transgenic mice Gtv-a mice that express the TVA receptor (the receptor for avian leucosis virus) from the GFAP promoter have been reported (Holland et al., 1998) . The mice are a mixed genetic background of C57BL6, 129, Balb/C and FVB/N. p53 null mice with a 129/SV and C57BL6 mixed genetic background have been described (Jacks et al., 1994) . The Gtv-a mouse line was crossbred with the p53 null line and genotyping of the progeny was done by using QIAamp DNA Mini Kit (Qiagen Inc., Valencia, CA, USA), PuReTaq Ready-To-Go PCR Beads (GE Healthcare, Buckinghamshire, UK) and indicated primers for Gtv-a, Ntv-a and p53 (see Supplementary Figure 4 for sequences). Thermocycling conditions consisted of 5 min at 95 1C, 40 cycle of 30 s at 95 1C, 30 s at 55 1C and 45 s at 72 1C, followed by 10 min at 72 1C.
DNA constructs and transfection of DF1 cells
The RCAS/tv-a system used in this work has been described previously (Holland et al., 2000) . RCAS-c-Myc plasmid, which contains full-length, wild-type human c-Myc was a gift from Daniel W Fults (University of Utah School of Medicine). RCAS-b-catenin, which carries the gene encoding the S37A point mutant-activated human b-catenin, was kindly provided by Harold E Varmus (Memorial Sloan-Kettering Cancer Center). Transfection of RCAS constructs into chicken DF1 fibroblasts was done as described previously (Dai et al., 2001) . DNA sequencing of c-Myc and b-catenin was done by ABI 3730 capillary sequencer (Applied Biosystems, Foster City, CA, USA) using indicated primers (Supplementary Figure 4) . Genotyping of RCAS-c-Myc and RCAS-b-catenin was done by PCR same as above using primers listed in Supplementary  Figure 4 .
Generation of tumor-bearing mice Neonatal mice received intracranial injections of approximately 10 4 DF1 cells producing the RCAS-c-Myc retrovirus or both 5 Â 10 3 DF1 cells producing the RCAS-c-Myc retrovirus and 5 Â 10 3 DF1 cells producing RCAS-b-catenin retrovirus. Mice were then monitored daily for symptoms of tumor development (hydrocephalus and lethargy). Symptomatic mice were killed and examined histologically. As p53 À/À mice die from cancer such as lymphoma and sarcoma, the majority of the mice have been killed at 12 weeks of age. Five mice bearing c-Myc-induced tumor were observed after 12 weeks to evaluate latency. Genotyping and DNA sequencing of mouse tissues were done same as above using primers listed in Supplementary Figure 4 .
Brain sectioning, H&E staining and immunohistochemistry These procedures were performed as described previously (Dai et al., 2001) . Primary mouse monoclonal antibodies against b-catenin (BD Biosciences, San Jose, CA, USA, 14), neuronal nuclei (Chemicon International Inc., Temecula, CA, USA, NeuN), neuronal class III b-tubulin (Covance, Inc., Princeton, NJ, USA, TUJ1), GFAP (Chemicon, G-A-5), cytokeratin 18 (Chemicon, Ks18.04), smooth muscle actin (DAKO Corporation, Carpinteria, CA, USA, 1A4), c-Myc (Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA, 9E10) and c-Myc (Novocastra Laboratories Ltd, Newcastle upon Tyne, UK, 9E11) were used with indicated dilutions using MOM kit (Vector BioLabs, Philadelphia, PA, USA) according to the manufacture's instructions. Primary rat monoclonal antibody against CD45R (BD Biosciences, RA3-6B2) and rabbit polyclonal antibodies against Ki-67 (Vector, VP-K451), c-Myc (Santa Cruz, N262) and p53 (Vector, CM5) were diluted in 1.5% goat serum PBS-Tween 0.1% with indicated dilutions by suppliers. Secondary biotinylated anti-rabbit or anti-rat antibody (Vector) was used at 1:200 dilution. Peroxidase signal was detected using the ABC elite kit (Vector) and DAB substrate kit (Vector). Double staining was performed by using DAB substrate kit, VIP substrate kit (Vector) and methyl green nuclear counterstain (Vector).
Fluorescence in situ hybridization Biotin-labeled DNA probe was made from RCAS-Y vector using BioNick Labeling System (Invitrogen Corporation, Carlsbad, CA, USA). The DNA probe was purified using QIAquick PCR Purification Kit (Qiagen). Paraffin embedded tissues were deparaffinized and microwaved in the untigen unmasking solution (Vector). Three-microliter DNA probe (0.12 mg DNA) was mixed with 13 ml hybridization solution (50% formamide, 10% dextran sulfate, 2 Â SSC, 1 mM EDTA, 5 mM Tris-HCl pH (7.6) and 1 mg salmon sperm DNA), heated at 80 1C for 5 min and applied onto the slide and sealed with a cover slip. The section was denatured at 75 1C for 5 min, and incubated at 37 1C overnight. Then, the slide was washed in 50% formamide 2 Â SSC solution at 45 1C for 5min twice and blocked with 5% dry milk. Texas Red Avidin D (Vector) was used at 1:200 dilution for 30 min at room temperature, and the signal was amplified by using biotinylated anti-Avidin D (Vector) at 1:100 dilution for 30 min at room temperature followed by Texas Red Avidin D again. The slide was stained with DAPI and examined with an Axioplan 2 fluorescent microscope (Carl Zeiss MicroImaging, Inc., Thornwood, NY, USA).
Electron microscopy
Representative fresh tumor tissue was fixed in 10% neutral buffered formalin. After buffer rinse, the tissue was post-fixed in 1% osmium tetroxide, dehydrated in graded ethanol, cleared in propylene oxide and embedded in epoxy resin using standard procedures. In each case, thick sections were cut and stained with toluidine blue, and representative blocks were chosen for ultrastructural evaluation. Thin sections were stained with uranyl acetate followed by lead citrate and examined with a Philips EM 410 electron microscope.
Statistical analysis
In mouse experiments, overall survival was measured using the Kaplan-Meier method, and Student's t-test was used for group comparison. In histopathological analysis, Fisher's exact probability test was used for comparison between two groups. Statistical analysis was performed with Statcel software (OMS Publishing Inc., Tokyo, Japan). Data represent the mean ± s.d. P-values of o0.05 were considered statistically significant.
